ADVERTISEMENT



Google       

Home -> Law Blog Directory -> Legal News Blogs -> FindLaw's Common Law

OR PHONE (866) 635-1838 for Bankruptcy Help, (866) 635-6190 for Divorce,
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense

Find a Local Lawyer

Bankruptcy (866) 635-1838
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402

Bookmark

Legal News

: FindLaw's Common Law

Latisse Side Effects: FDA Warns Allergan over Misleading Claims

ADVERTISEMENTS

Latisse wants you to "Look who's growing longer, fuller, darker lashes." Unfortunately for Latisse and it maker Allergan, Inc, the FDA wants you to look at who may be growing unwanted non-eyelash hair, getting brown pigmentation (possibly permanent) in their irises, getting brown pigmentation on their eyelids, and possibly having allergic reactions.

Here is the warning letter sent by the FDA to Latisse maker Allergan, who brought us Botox, amongst other hit cosmetic drugs.

The FDA is concerned about the "FAQs" and "About Safety" pages on the Latisse website. It appears, that in addition to watching Brooke Shields' remarkable eyelash journey made possible by Latisse, consumers might encounter some less than forthcoming claims about risks associated with the cosmetic drug.

This is not about failure to include something in the fine print of an ad or laundry list at the end of a TV commercial, but instead about the website where consumers go to find out basic information about what risks Latisse might have.

The FDA's problems with the Latisse site include:

  • Warning users not to apply latisse to the lower lashes, but not telling them why -- because applying them to the lower lashes could cause unwanted hair growth below;
  • Stating that "similar" medications have cause some brown pigmentation to seep into the iris of people's eyes, when actually the same active ingredient in Latisse has caused this; and
  • Misleadingly stating that eye redness and itching associated with Latisse are not allergic reactions.

The FDA has demanded that Allergan respond by September 24 and get rid of the misleading claims.


Full post as published by FindLaw's Common Law on September 18, 2009 (boomark / email).

Bloggers, promote your law blog by nominating your blog for inclusion in USLaw.com's Law Blog Directory and RSS Reader. Benefits described.
Related Law Articles

Lawsuits and Settlements

Related Searches

























































































































US Law
#1 Online Legal Resource













Your Blog Subscriptions
Subscribe to blogs

10,000+ Law Job Listings
Lawyer . Police . Paralegal . Etc
Earn a law-related degree
Are you the author of this blog? Adding USLaw.com to your Blogroll increases relevance. You qualify to display a USLaw Network badge.
Suggest changes to this blog's description or nominate another for inclusion. Register for updates.


Practice Area
Zip Code:

Contact a Lawyer Now!






0.0135 secs (new cache)